1 / 20

Pharmacovigilance (PV)

Pharmacovigilance (PV). Pharmacovigilance (PV). PV is concerned with detection , assessment & prevention of adverse reactions to drugs (ADRs) or any drug-related problems. 2. Drug-Related Problems. Lack of efficacy. Manufacturing defects. Medication errors. Drug misuse and abuse.

moswen
Télécharger la présentation

Pharmacovigilance (PV)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacovigilance (PV)

  2. Pharmacovigilance (PV) • PVis concerned withdetection, assessment & prevention of adverse reactions to drugs (ADRs) or any drug-related problems 2

  3. Drug-Related Problems • Lack of efficacy. • Manufacturing defects. • Medication errors. • Drug misuse and abuse. • Overdose. • Contamination. • Counterfeit products. 3

  4. Recently, the concerns of PV have been widened to include: • Herbal • Traditional and complementary medicines • Blood products • Biologicals • Medical devices • Vaccines 4

  5. Why Pharmacovigilance? • The root of pharmacovigilance: Pharmaco (Greek)= Drug Vigilance (Latin)= to keep awake or alert • Because information collected during pre-marketing phase are incomplete with regard to possible ADR • Tests in animals are insufficiently predictive of human safety

  6. Why Pharmacovigilance? 6 • In clinical trials: • Patients are limited in number • Conditions of use differ from those in clinical practice • Duration of trials is limited

  7. Why Pharmacovigilance? Post-marketing surveillance by companies is therefore essential • Information about rare adverse reactions, chronic toxicity, use in special groups (children, elderly or pregnant women) or drug interactions is often incomplete or not available

  8. Why Pharmacoviglance? • Pre-marketing clinical trialsdo not have : • Statistical power to detect rare ADRs • To identify delayed ADRs • To identify effects from long-term exposure PV plays a prominent role in establishing safety profile of marketed drugs 8

  9. 9

  10. Definition of ADR • An ADRis defined according to definition of WHO“any response to a drug which is noxious, unintended& thatoccurs at dosesused in man for prophylaxis, diagnosis, or therapy of diseases’’ 10

  11. Epidemiology of ADRs ADRs represent a significant cause ofmorbidity & mortality Many ADRs aremild, sometimesserious& cancause death U.S, ADRs caused100 000deaths per year, 4th & 6thleading cause of death About 50% of ADRs are preventable 11

  12. Importance of ADRs Prolonglength of stay in hospitals Increasecostsof patient care Commonest cause ofdrug withdrawal from market: Reductil (Sibutramine) 2010 Valdecoxib (Bextra) 2005 Rofecoxib (Vioxx) 2004 12

  13. ADRs is considered serious if: Causesdeath of patient Life-threatening Prolonginpatient hospitalisation Causessignificant or persist disability Congenital abnormality 13

  14. Risk Factors predisposing to ADRs • Age • Long duration of treatment • Polypharmacy • Liver, kidney diseases

  15. Causes of ADRs • Patient • Drug • Prescriber • Environmental factors

  16. Causes of ADRs 2. The drug - Narrow therapeutic index, e.g. warfarin, digoxin - Antimicrobials have a tendency to cause allergy - Ingredients of a formulation, e.g. colouring, flavouring 16

  17. Drugs most commonly causing ADRs • Warfarin • Diuretics • Digoxin • Antibacterials • Steroids • Antihypertensives Anticancer drugs Immunomodulators Analgescis

  18. Why report suspected ADRs? • Documentation of ADRs in patients’ records is often poor • Physicians fear that reporting of ADR may put them at risk • Under-reportingis common phenomenon 18

  19. Reporting Methods Spontaneous reporting: (Voluntary) • Doctors, nurses & pharmacists are supplied with forms to record suspected ADRs • Reporting ADRs to National Pharmacovigilance Centre • In UK, this is called ‘Yellow Card system’

  20. Prevention of ADRs • Taking a drug history • Reduce number of prescribed drugs • Remembering that certain patients (elderly, those with liver or renal diseases) more susceptible to ADRs

More Related